正大天晴重组人凝血因子VIIa获批上市;拨康视云上市首日破发

氨基观察
Jul 03

正大天晴又有新收获。7月3日,据NMPA官网,正大天晴的注射用重组人凝血因子VIIa(TQG203)已获批上市,适应症为抑制物阳性先天性血友病A或B患者以及某些特定类型罕见出血性疾病患者群体出血的治疗和外科手术或有创操作出血的防治。不是所有的18A,都能上市大涨。7月3日,创新药企拨康视云港股上市。二级市场方面,公司表现不佳,上市首日破发,大跌38.61%。在过去的一天里,国内外医药市场还有哪些...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10